当前位置: X-MOL 学术Med. Res. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Phage therapy: Current status and perspectives.
Medicinal Research Reviews ( IF 13.3 ) Pub Date : 2019-05-07 , DOI: 10.1002/med.21593
Andrzej Górski 1 , Ryszard Międzybrodzki 1, 2 , Grzegorz Węgrzyn 3 , Ewa Jończyk-Matysiak 1 , Jan Borysowski 2 , Beata Weber-Dąbrowska 1
Affiliation  

The spread of antimicrobial resistant bacterial pathogens combined with the lack of new drug classes in the antibiotic pipeline causes a resurgence of the use of bacterial viruses (phages) to treat bacterial infections (phage therapy [PT]). There has been a substantial increase in patients subjected to this experimental therapy and emergence of new PT centers in Europe and the United States paralleled by one clinical trial completed in accord with good medical practice (GMP) requirements and a few others underway. What is more, evidence has been accumulating to suggest that phages can also exert anti‐inflammatory and immunomodulatory action which opens new pathways for the development of novel targets for PT. Here we present the status quo of the PT, recent regulatory, and clinical developments as well as new perspectives for its wider application in clinical medicine.

中文翻译:

噬菌体疗法:现状和观点。

抗菌素耐药性细菌病原体的传播加上抗生素管道中缺乏新药类别,导致使用细菌病毒(噬菌体)治疗细菌感染的复兴(噬菌体治疗[PT])。接受这种实验性治疗的患者数量大大增加,同时在欧洲和美国建立了新的PT中心,同时一项符合良好医学规范(GMP)要求的临床试验已经完成,其他一些正在进行中。而且,越来越多的证据表明,噬菌体也可以发挥抗炎和免疫调节作用,这为开发新的PT靶标开辟了新途径。在这里,我们介绍PT的现状,最近的法规,
更新日期:2019-05-07
down
wechat
bug